Search Results for "Cisplatin And Taxol For Adenocarcinoma Lung"
Original Source: Pemetrexed and Cisplatin or Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether pemetrexed is more effective when given together with cisplatin or paclitaxel in treating patients with non-small cell lung cancer. PURPOSE: This rando...
Matching Channels
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common ca...
Matching News
Molecular driven therapeutic targets have resulted in a paradigm shift in the treatment of advanced lung adenocarcinoma. However, in early non-small cell lung cancer (NSCLC), surgical resection remain...
Potential biomarker to predict lung cancer patients' response to chemotherapy
Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cispl...
Treatment of non-small cell lung cancer and adenocarcinoma
Dr Keith Kerr discusses the molecular characteristics of adenocarcinoma at EMCTO 2013 in Lugano, Switzerland. With non-small cell lung cancer, there are a large number of abnormalities and mutations,...
Takashi Kohno and colleagues identify two new susceptibility loci for lung adenocarcinoma in the Japanese population. They also replicate previously identified risk loci near TERT and TP63.
PARP Inhibitors Destroy Cisplatin-Resistant Lung Cancer Cells
After relapse from treatment with the chemotherapeutic drug cisplatin, some types of cancer cells become dependent on the activity...
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that a Phase I study of CP-4126 (CO-101) in combination with cisplatin in non-small-cell lung cancer (NSCLC) h...
Pathologists identify patterns of mutations to help inform design of future trials
(International Association for the Study of Lung Cancer) Molecular driven therapeutic targets have resulted in a paradigm shift in the treatment of advanced lung adenocarcinoma. However, in early non-...
Erbitux fails in gastric cancer trial
Merck’s Erbitux has failed to increase survival in patients with gastric cancer, representing a blow to the firm’s ambition to extend its licence. The Phase III EXPAND trials assessed Erbitux (cet...
Matching PubMed Articles
The BCL2 family of proteins includes apoptosis-related molecules involved in normal physiology, as well as cancer pathology. Members of our team have discovered and cloned the novel gene BCL2L12, whic...
RNA Interference Targeting GRP75 Decreases Cisplatin Resistance in Human Lung Adenocarcinoma Cell.
BACKGROUND: GRP75, a member of HSPs which is overexpressed in some resistant cancer cells, is a molecular chaperone mainly located in mitochondrial membrane. The aim of this study is to investigate th...
Advances of DNA damage repair and Cisplatin resistance mechanisms in lung cancer.
Lung cancer is the most common cause of death from cancer worldwide per year. Platinum-based combination chemotherapy is a main treatment of lung cancer. Cisplatin is adopted widely and used effective...
Thyroid carcinomas and lung adenocarcinoma share cytomorphological features yet have different prognoses. Thyroid Transcription Factor-1 (TTF-1) is an immunohistochemical (IHC) marker used to confirm...
OBJECTIVE: To investigate the correlation of vascular endothelial growth factor (VEGF) A and its isoform VEGF (121) mRNA expression with F-18 fluorodeoxyglucose (FDG) uptake and aggressiveness in lung...
